Welcome to our dedicated page for Alkermes plc. SEC filings (Ticker: ALKS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alkermes plc filings document a Nasdaq-listed Irish public limited biopharmaceutical company focused on neuroscience medicines. The record includes 8-K reports for operating results, financial expectations, investor presentations, material definitive agreements and Regulation FD disclosures, along with proxy materials for annual general meeting matters, director elections, executive compensation and shareholder voting.
Capital-structure disclosures cover ordinary shares listed under ALKS and senior secured term loan facilities used in connection with completed acquisition activity. Material-event reports also address governance and executive transition matters, compensatory arrangements, commercial-product performance and clinical-stage disclosures for the company’s orexin 2 receptor agonist programs.
Alkermes plc. SVP and Chief Commercial Officer Christian Todd Nichols reported open-market sales of Alkermes ordinary shares. On 2026-08-17, he sold 6,912 shares at a weighted average price of $49.1851 and 664 shares at a weighted average price of $49.6526, in transactions made under a Rule 10b5-1 trading plan. Each sale was executed through multiple trades within disclosed price ranges.
Alkermes plc has a beneficial owner planning to sell 7,576 shares of common stock through Merrill Lynch on NASDAQ. The proposed sale has an aggregate market value of $372,936.86 and is scheduled on or after August 17, 2026.
The seller previously acquired Alkermes common stock through vesting of restricted stock unit awards, including 2,473 shares on February 23, 2025, 3,952 shares on February 22, 2025, and 1,151 shares on February 18, 2025 under the issuer’s equity compensation plan.
Alkermes plc entered into Amendment No. 1 to its existing senior secured credit agreement, which governs a term loan A facility and a term loan B facility. The term loan A facility has an outstanding principal amount of $745,312,500 and matures on February 12, 2031, while the term loan B facility has an outstanding principal amount of $773,062,500 and matures on August 12, 2031.
The amendment reduces the interest rate spread on these facilities, lowering the spread on the term loan A facility by 0.75% and on the term loan B facility by 0.50%. After the changes, borrowings under the term loan A facility bear interest at either the Term SOFR Rate plus a Secured Net Leverage Ratio-based margin of 1.75%–2.25% per year, or the Alternate Base Rate plus a margin of 0.75%–1.25%. Borrowings under the term loan B facility bear interest at either the Term SOFR Rate plus 2.25% per year or the Alternate Base Rate plus 1.25%, at the company’s option.
Alkermes plc reported that President & CEO Jackson Blair Curtis received two grants of Employee Stock Options on 2026-08-05. One award covers 93,229 options with an exercise price of $49.6100 per share, vesting in four equal annual installments commencing on 8/5/2027 and expiring on 2036-08-05. A second award covers 124,305 options at the same exercise price and expiration, vesting in two tranches only if Alkermes’s ordinary share trades at certain pre-specified price levels for 30 consecutive trading days and after two years of continuous service as CEO, or less in the event of a change in control.
Nancy Lynn Snyderman, a director of Alkermes plc, exercised fully vested non-qualified stock options to acquire 44,472 Ordinary Shares at an exercise price of $46.72 per share on August 3, 2026. She then sold 44,472 shares at a weighted average price of $50.3480 per share, in transactions priced between $50.07 and $50.70. Following these transactions, 20,783 Ordinary Shares are held indirectly through the Nancy Lynn Snyderman Revocable Trust.
Alkermes plc. executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, exercised employee stock options for a total of 5,000 ordinary shares at exercise prices of $19.34 and $24.59, and on 2026-08-03 sold 9,000 ordinary shares at $48.58 per share. These option exercises and the share sale were effected pursuant to a Rule 10b5-1 trading plan adopted on 3/14/2025, and the exercised options were fully vested.
On 2026-08-03, Alkermes plc executive David Joseph Gaffin, EVP and CLO, sold 2,034 Ordinary Shares of Alkermes at an average price of $48.58 per share. The sale, reported as a sale in the open market or a private transaction, was executed under a Rule 10b5-1 trading plan adopted on 11/19/2025, and he now directly holds 225,456 Ordinary Shares.
Alkermes plc insider David Gaffin plans potential sales of Alkermes common stock through Merrill Lynch, with an aggregate market value of $98,811.72 and reference to 167,763,272 shares outstanding as of 08/03/2026. The shares relate to prior restricted stock unit and performance share unit awards granted under the issuer’s equity compensation plan that vested between 2014 and 2016. Gaffin has also reported multiple open-market sales of 2,034 shares each month from April through July 2026, with gross proceeds ranging from $70,315.38 to $109,897.02.
Craig Hopkinson, an affiliate of Alkermes plc, plans to sell 9,000 ordinary shares through Merrill Lynch on August 3, 2026, with an estimated aggregate value of $437,220.00. The shares derive from an employee stock option exercise and vesting of performance and restricted stock awards. The filing also lists five prior open-market sales of 9,000 shares each month from March through July 2026, with proceeds between $267,485.14 and $463,620.68.